The DOI matches its Crossref record; 218 of the 218 references it cites were found in a registry or an index.
Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: Current progress and advances
Open accessAbstract
Chemotherapeutic agents have certain limitations when it comes to treating cancer, the most important being severe side effects along with multidrug resistance developed against them. Tumor cells exhibits drug resistance due to activation of various cellular level processes viz. activation of drug efflux pumps, anti-apoptotic defense mechanisms etc. Currently, RNA interference (RNAi) based therapeutic approaches are under vibrant scrutinization to seek cancer cure. Especially small interfering RNA (siRNA) and micro RNA (miRNA), are able to knock down the carcinogenic genes by targeting the mRNA expression, which underlies the uniqueness of this therapeutic approach. Recent research focus in the regime of cancer therapy involves the engagement of targeted delivery of siRNA/miRNA in combinations with other therapeutic agents (such as gene, DNA or chemotherapeutic drug) for targeting permeability glycoprotein (P-gp), Multidrug resistant protein 1(MRP-1), B-cell lymphoma (BCL-2) and other targets that are mainly responsible for resistance in cancer therapy. RNAi-chemotherapeutic drug combinations have also been found to be effective against different molecular targets as well and can increase the sensitization of cancer cells to therapy several folds. However, due to stability issues associated with siRNA/miRNA suitable protective carrier is needed and nanotechnology based approaches have been widely explored to overcome these drawbacks. Furthermore, it has been univocally advocated that the co-delivery of siRNA/miRNA with other chemodrugs significantly enhances their capability to overcome cancer resistance compared to naked counterparts. The objective of this article is to review recent nanocarrier based approaches adopted for the delivery of siRNA/miRNA combinations with other anticancer agents (siRNA/miRNA/pDNA/chemodrugs) to treat cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
RETRACTED: The Role of microRNAs in the Tumorigenesis of Ovarian Cancer
Leva, G. D., & Croce, C. M. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00153 · Cited by 98
RetractedRETRACTED: Polyethylenimine nanoparticles as efficient transfecting agents for mammalian cells
Nimesh, S., Goyal, A., Pawar, V., Jayaraman, S., Kumar, P., Chandra, R., Singh, Y. P., & Gupta, K. C. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.10.014 · Cited by 97
RetractedBartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Boussif, O., Lezoualc'h, F., Zanta, M. A., Mergny, M. D., Scherman, D., Demeneix, B., & Behr, J. P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.16.7297 · Cited by 6,247
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
Alexopoulou, L., Holt, A. C., Medzhitov, R., & Flavell, R. A. (2001) · Nature · doi:10.1038/35099560 · Cited by 6,129
Hengartner, M. O. (2000) · Nature · doi:10.1038/35037710 · Cited by 5,779
Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast Carcinoma
Weidner, N., Semple, J. P., Welch, W. R., & Folkman, J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101033240101 · Cited by 5,627
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, S., Coebergh, J. W. W., Comber, H., Forman, D., & Bray, F. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.027 · Cited by 5,263
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681 · cited 1×
“The drug resistancemechanism is explained in detail elsewhere [72,76].”
BackgroundThe widespread regulation of microRNA biogenesis, function and decay
Krol, J., Loedige, I., & Filipowicz, W. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2843 · Cited by 4,672
Cancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
What Is the Evidence That Tumors Are Angiogenesis Dependent?
Folkman, J. (1990) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/82.1.4 · Cited by 4,531
Toll-like receptors and innate immunity
Medzhitov, R. (2001) · Nature Reviews Immunology · doi:10.1038/35100529 · Cited by 4,308
A New Class of Polymers: Starburst-Dendritic Macromolecules
Tomalia, D. A., Baker, H., Dewald, J., Hall, M., Kallos, G., Martin, S., Roeck, J., Ryder, J., & Smith, P. (1985) · Polymer Journal · doi:10.1295/polymj.17.117 · Cited by 3,904
Drug delivery and nanoparticles: Applications and hazards
de Jong (2008) · International Journal of Nanomedicine · doi:10.2147/ijn.s596 · Cited by 3,848
Biodegradable polymeric nanoparticles based drug delivery systems
Kumari, A., Yadav, S. K., & Yadav, S. C. (2010) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2009.09.001 · Cited by 3,724
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
Folkman, J., & Klagsbrun, M. (1987) · Science · doi:10.1126/science.2432664 · Cited by 3,491
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115
Nanoparticles in cancer therapy and diagnosis
Brigger, I., Dubernet, C., & Couvreur, P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00044-3 · Cited by 3,039
Many roads to maturity: microRNA biogenesis pathways and their regulation
Winter, J., Jung, S., Keller, S., Gregory, R. I., & Diederichs, S. (2009) · Nature Cell Biology · doi:10.1038/ncb0309-228 · Cited by 2,656
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643
Expression profiling reveals off-target gene regulation by RNAi
Jackson, A. L., Bartz, S. R., Schelter, J., Kobayashi, S. V., Burchard, J., Mao, M., Li, B., Cavet, G., & Linsley, P. S. (2003) · Nature Biotechnology · doi:10.1038/nbt831 · Cited by 2,370
About Dendrimers: Structure, Physical Properties, and Applications
Bosman, A. W., Janssen, H. M., & Meijer, E. W. (1999) · Chemical Reviews · doi:10.1021/cr970069y · Cited by 2,343
The Bcl-2 apoptotic switch in cancer development and therapy
Adams, J. M., & Cory, S. (2007) · Oncogene · doi:10.1038/sj.onc.1210220 · Cited by 2,176
Crooks, R. M., Zhao, M., Sun, L., Chechik, V., & Yeung, L. K. (2001) · Accounts of Chemical Research · doi:10.1021/ar000110a · Cited by 2,115
Nanoparticle PEGylation for Imaging and Therapy
Jokerst, J. V., Lobovkina, T., Zare, R. N., & Gambhir, S. S. (2011) · Nanomedicine · doi:10.2217/nnm.11.19 · Cited by 2,046
Chargaff, E., & Davidson, J. N. (1955) · Cited by 2,043
Johnstone (2002) · doi:10.1016/s0092-8674(02)00625-6 · Cited by 1,876
MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship
Pasquinelli, A. E. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3162 · Cited by 1,593
Multidrug-resistance efflux pumps ? not just for resistance
Piddock, L. J. V. (2006) · Nature Reviews Microbiology · doi:10.1038/nrmicro1464 · Cited by 1,522
Leslie, E. M., Deeley, R. G., & Cole, S. P. C. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.10.012 · Cited by 1,406
Gabizón, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A., & Barenholz, Y. (1994) · PubMed · Cited by 1,382
Exploring polyethylenimine‐mediated DNA transfection and the proton sponge hypothesis
Akinc, A., Thomas, M., Klibanov, A. M., & Langer, R. (2005) · The Journal of Gene Medicine · doi:10.1002/jgm.696 · Cited by 1,337
Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer
Malam, Y., Loizidou, M., & Seifalian, A. M. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.08.004 · Cited by 1,318
Interfering with disease: a progress report on siRNA-based therapeutics
de Fougerolles, A., Vornlocher, H.-P., Maraganore, J., & Lieberman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2310 · Cited by 1,203
Xiao, K., Li, Y., Luo, J., Lee, J. S., Xiao, W., Gonik, A. M., Agarwal, R. G., & Lam, K. S. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.01.021 · Cited by 1,039
The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC
Fabian, M. R., & Sonenberg, N. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2296 · Cited by 1,025
A Brief Review on the Mechanisms of miRNA Regulation
Cai, Y., Yu, X., Hu, S., & Yu, J. (2009) · Genomics, Proteomics & Bioinformatics · doi:10.1016/s1672-0229(08)60044-3 · Cited by 1,001
Inorganic nanoparticles as carriers for efficient cellular delivery
Xu, Z. P., Zeng, Q. H., Lu, G. Q., & Yu, A. B. (2006) · Chemical Engineering Science · doi:10.1016/j.ces.2005.06.019 · Cited by 976
Meng, H., Liong, M., Xia, T., Li, Z., Ji, Z., Zink, J. I., & Nel, A. E. (2010) · ACS Nano · doi:10.1021/nn100690m · Cited by 902
Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system
Storm, G., Belliot, S. O., Daemen, T., & Lasic, D. D. (1995) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00039-a · Cited by 877
Neu, M., Fischer, D., & Kissel, T. (2005) · The Journal of Gene Medicine · doi:10.1002/jgm.773 · Cited by 866
A Polyamidoamine Dendrimer-Capped Mesoporous Silica Nanosphere-Based Gene Transfection Reagent
Radu, D. R., Lai, C.-Y., Jeftinija, K., Rowe, E. W., Jeftinija, S., & Lin, V. S.-Y. (2004) · Journal of the American Chemical Society · doi:10.1021/ja046275m · Cited by 840
Mesoporous Silica Nanoparticles for Intracellular Delivery of Membrane-Impermeable Proteins
Slowing, I. I., Trewyn, B. G., & Lin, V. S.-Y. (2007) · Journal of the American Chemical Society · doi:10.1021/ja0719780 · Cited by 795
Ma, S., Lee, T. K., Zheng, B.-J., Chan, K. W., & Guan, X.-Y. (2008) · Oncogene · doi:10.1038/sj.onc.1210811 · Cited by 775
Liotta, L. A., Kleinerman, J. I., & Saidel, G. M. (1974) · PubMed · Cited by 766
Current prospects for RNA interference-based therapies
Davidson, B. L., & McCray, P. B. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2968 · Cited by 761
Conjugation of Biomolecules with Luminophore-Doped Silica Nanoparticles for Photostable Biomarkers
Santra, S., Zhang, P., Wang, K., Tapec, R., & Tan, W. (2001) · Analytical Chemistry · doi:10.1021/ac010406+ · Cited by 756
Fonseca, C., Simões, S., & Gaspar, R. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00212-2 · Cited by 755
Chitosan nanoparticles as delivery systems for doxorubicin
Janes, K. A., Fresneau, M. P., Marazuela, A., Fabra, A., & Alonso, M. J. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00294-2 · Cited by 721
Nanoparticle-based combination therapy toward overcoming drug resistance in cancer
Hu, C.-M. J., & Zhang, L. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.01.008 · Cited by 686
Dendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issues
Pandita, D., Madaan, K., Kumar, S., Poonia, N., & Lather, V. (2014) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/0975-7406.130965 · Cited by 679
Chen, A. M., Zhang, M., Wei, D., Stueber, D., Taratula, O., Minko, T., & He, H. (2009) · Small · doi:10.1002/smll.200900621 · Cited by 671
Dendrimers as Carriers for Delivery of Chemotherapeutic Agents
Medina, S. H., & El-Sayed, M. E. H. (2009) · Chemical Reviews · doi:10.1021/cr900174j · Cited by 669
Trang, P., Wiggins, J. F., Daige, C. L., Cho, C., Omotola, M., Brown, D., Weidhaas, J. B., Bader, A. G., & Slack, F. J. (2011) · Molecular Therapy · doi:10.1038/mt.2011.48 · Cited by 667
Recent advances of chitosan nanoparticles as drug carriers
Zeng, Z. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s17296 · Cited by 665
Chitosan Nanoparticles: A Promising System in Novel Drug Delivery
Nagpal, K., Singh, S. K., & Mishra, D. N. (2010) · CHEMICAL & PHARMACEUTICAL BULLETIN · doi:10.1248/cpb.58.1423 · Cited by 660
Polymeric Micelles for Drug Delivery
Croy, S., & Kwon, G. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206779026245 · Cited by 603
Borm, P., Klaessig, F. C., Landry, T. D., Moudgil, B., Pauluhn, J., Thomas, K., Trottier, R., & Wood, S. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfj084 · Cited by 586
Inorganic Nanoparticles as Carriers of Nucleic Acids into Cells
Sokolova, V., & Epple, M. (2008) · Angewandte Chemie International Edition · doi:10.1002/anie.200703039 · Cited by 581
Meng, H., Mai, W. X., Zhang, H., Xue, M., Xia, T., Lin, S., Wang, X., Zhao, Y., Ji, Z., Zink, J. I., et al. (2013) · ACS Nano · doi:10.1021/nn3044066 · Cited by 575
Nanotherapeutics to Overcome Conventional Cancer Chemotherapy Limitations
Chidambaram, M., Manavalan, R., & Kathiresan, K. (2011) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j30c7d · Cited by 566
PEGylated PLGA nanoparticles as protein carriers: Synthesis, preparation and biodistribution in rats
Li, Y.-P., Pei, Y.-Y., Zhang, X.-Y., Gu, Z.-H., Zhou, Z.-H., Yuan, W.-F., Zhou, J.-J., Zhu, J.-H., & Gao, X.-J. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00218-8 · Cited by 540 · cited 9×
“U N C O R R E C [107], polymers poly (D,L-lactide-co-glycolide) (PLGA) [108,109], poly lactic acid (PLA) [110,111], poly capro lactone (PCL) [112–114]), dendrimers [115,116], and silica [117–119] have been used to deliver the siRNA based combinations to treat cancer.”
MethodInfluentialTiscornia, G., Singer, O., Ikawa, M., & Verma, I. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437912100 · Cited by 540
Roles for Growth Factors in Cancer Progression
Witsch, E., Sela, M., & Yarden, Y. (2010) · Physiology · doi:10.1152/physiol.00045.2009 · Cited by 526
Nanoparticles Modified With Tumor-targeting scFv Deliver siRNA and miRNA for Cancer Therapy
Chen, Y., Zhu, X., Zhang, X., Liu, B., & Huang, L. (2010) · Molecular Therapy · doi:10.1038/mt.2010.136 · Cited by 515
RNAi: nature abhors a double-strand
Hutvágner, G., & Zamore, P. D. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(02)00290-3 · Cited by 508
Biodegradable poly(ε-caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen
Chawla, J. S., & Amiji, M. M. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00483-0 · Cited by 487
Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery
Li, J., Chen, Y.-C., Tseng, Y.-C., Mozumdar, S., & Huang, L. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.11.008 · Cited by 470
Dong, Y., & Feng, S.-S. (2004) · Biomaterials · doi:10.1016/j.biomaterials.2003.09.055 · Cited by 468
Nonviral delivery of synthetic siRNAs in vivo
Akhtar, S., & Benter, I. F. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33494 · Cited by 464
Venturoli, D., & Rippe, B. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00171.2004 · Cited by 461
Sivori, S., Falco, M., Chiesa, M. D., Carlomagno, S., Vitale, M., Moretta, L., & Moretta, A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403744101 · Cited by 455
Biochemically functionalized silica nanoparticles
Qhobosheane, M., Santra, S., Zhang, P., & Tan, W. (2001) · The Analyst · doi:10.1039/b101489g · Cited by 452
Current progress of siRNA/shRNA therapeutics in clinical trials
Burnett, J. C., Rossi, J. J., & Tiemann, K. (2011) · Biotechnology Journal · doi:10.1002/biot.201100054 · Cited by 444
Zhu, C., Jung, S., Luo, S., Meng, F., Zhu, X., Park, T. G., & Zhong, Z. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2009.11.077 · Cited by 440
Wood, A. J. J., & Ihde, D. C. (1992) · New England Journal of Medicine · doi:10.1056/nejm199211123272006 · Cited by 428
Conde, J., Dias, J. T., Grazú, V., Moros, M., Baptista, P. V., & de la Fuente, J. M. (2014) · Frontiers in Chemistry · doi:10.3389/fchem.2014.00048 · Cited by 425
Well-Ordered Mesoporous Silica Nanoparticles as Cell Markers
Lin, Y.-S., Tsai, C.-P., Huang, H.-Y., Kuo, C.-T., Hung, Y., Huang, D.-M., Chen, Y.-C., & Mou, C.-Y. (2005) · Chemistry of Materials · doi:10.1021/cm051014c · Cited by 424
Multi-functional nanocarriers to overcome tumor drug resistance
Jabr-Milane, L. S., van Vlerken, L. E., Yadav, S., & Amiji, M. M. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.04.003 · Cited by 407
Sun, T.-M., Du, J.-Z., Yao, Y.-D., Mao, C.-Q., Dou, S., Huang, S.-Y., Zhang, P.-Z., Leong, K. W., Song, E.-W., & Wang, J. (2011) · ACS Nano · doi:10.1021/nn103349h · Cited by 406
Cell cycle and apoptosis: Common pathways to life and death
King, K. L., & Cidlowski, J. A. (1995) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240580206 · Cited by 406
Stealth PLA-PEG nanoparticles as protein carriers for nasal administration
Tobío, M., Gref, R., Sánchez, A., Langer, R., & Alonso, M. J. (1998) · Pharmaceutical Research · doi:10.1023/a:1011922819926 · Cited by 402
Polyethylenimine-based intravenous delivery of transgenes to mouse lung
Goula, D., Benoist, C., Mantero, S., Merlo, G., Levi, G., & Demeneix, B. (1998) · Gene Therapy · doi:10.1038/sj.gt.3300717 · Cited by 375
Polymersome carriers: From self-assembly to siRNA and protein therapeutics
Christian, D. A., Cai, S., Bowen, D. M., Kim, Y., Pajerowski, J. D., & Discher, D. E. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.09.025 · Cited by 371
Co-Delivery of siRNA and An Anticancer Drug for Treatment of Multidrug-Resistant Cancer
Saad, M., Garbuzenko, O. B., & Minko, T. (2008) · Nanomedicine · doi:10.2217/17435889.3.6.761 · Cited by 367
Kim, S. H., Jeong, J. H., Lee, S. H., Kim, S. W., & Park, T. G. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.03.008 · Cited by 362
Polverini, P. J., & Leibovich, S. J. (1984) · PubMed · Cited by 360
siRNA-based approaches in cancer therapy
Devi, G. R. (2006) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700931 · Cited by 353
The influence of structure on the activity and toxicity of Pt anti-cancer drugs
Hambley, T. W. (1997) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(97)00023-4 · Cited by 348
RNA interference and chemically modified small interfering RNAs
Manoharan, M. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.10.007 · Cited by 346
Tumor-targeted Delivery of siRNA by Self-assembled Nanoparticles
Li, S.-D., Chen, Y.-C., Hackett, M. J., & Huang, L. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300323 · Cited by 333
Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance
Creixell, M., & Peppas, N. A. (2012) · Nano Today · doi:10.1016/j.nantod.2012.06.013 · Cited by 331
Ahmed, F., Pakunlu, R. I., Srinivas, G., Brannan, A., Bates, F., Klein, M. L., Minko, T., & Discher, D. E. (2006) · Molecular Pharmaceutics · doi:10.1021/mp050103u · Cited by 330
Taratula, O., Garbuzenko, O. B., Kirkpatrick, P., Pandya, I., Savla, R., Pozharov, V. P., He, H., & Minko, T. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.06.019 · Cited by 328
2-(dimethylamino)ethyl methacrylate based (co)polymers as gene transfer agents
van de Wetering, P., Cherng, J.-Y., Talsma, H., Crommelin, D. J. A., & Hennink, W. E. (1998) · Journal of Controlled Release · doi:10.1016/s0168-3659(97)00248-4 · Cited by 326
In vitro degradation rates of partially N-acetylated chitosans in human serum
Vårum, K. M., Myhr, M. M., Hjerde, R. J. N., & Smidsrød, O. (1997) · Carbohydrate Research · doi:10.1016/s0008-6215(96)00332-1 · Cited by 322
Panyam, J., Sahoo, S. K., Prabha, S., Bargar, T., & Labhasetwar, V. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(03)00295-3 · Cited by 308
Li, J., Yang, Y., & Huang, L. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.10.020 · Cited by 306
Patil, Y. B., Swaminathan, S. K., Sadhukha, T., Ma, L., & Panyam, J. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2009.09.048 · Cited by 304
Yu, B., Zhang, Y., Zheng, W., Fan, C., & Chen, T. (2012) · Inorganic Chemistry · doi:10.1021/ic301050v · Cited by 299
Erbacher, P., Bettinger, T., Belguise-Valladier, P., Zou, S., Coll, J.-L., Behr, J.-P., & Remy, J.-S. (1999) · The Journal of Gene Medicine · doi:10.1002/(sici)1521-2254(199905/06)1:3<210::aid-jgm30>3.0.co;2-u · Cited by 295
Huang, D., Hung, Y., Ko, B., Hsu, S., Chen, W., Chien, C., Tsai, C., Kuo, C., Kang, J., Yang, C., et al. (2005) · The FASEB Journal · doi:10.1096/fj.05-4288fje · Cited by 289
Gao, S., Dagnaes-Hansen, F., Nielsen, E. J. B., Wengel, J., Besenbacher, F., Howard, K. A., & Kjems, J. (2009) · Molecular Therapy · doi:10.1038/mt.2009.91 · Cited by 286
Goh, K. C. (2000) · The EMBO Journal · doi:10.1093/emboj/19.16.4292 · Cited by 285
Overcoming the Innate Immune Response to Small Interfering RNA
Judge, A., & MacLachlan, I. (2008) · Human Gene Therapy · doi:10.1089/hum.2007.179 · Cited by 284
Silica nanoparticles modified with aminosilanes as carriers for plasmid DNA
Kneuer, C., Sameti, M., Haltner, E. G., Schiestel, T., Schirra, H., Schmidt, H., & Lehr, C.-M. (2000) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(99)00435-4 · Cited by 276
Generation of Polymerosomes from Double-Emulsions
Lorenceau, E., Utada, A. S., Link, D. R., Cristobal, G., Joanicot, M., & Weitz, D. A. (2005) · Langmuir · doi:10.1021/la050797d · Cited by 272
Polymeric nanoparticles for siRNA delivery and gene silencing
Patil, Y., & Panyam, J. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.09.039 · Cited by 270
Chitosan-based siRNA delivery systems
Ragelle, H., Vandermeulen, G., & Préat, V. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.08.005 · Cited by 261
Drug delivery of siRNA therapeutics: potentials and limits of nanosystems
Reischl, D., & Zimmer, A. (2009) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2008.06.001 · Cited by 253
Filleur, S., Courtin, A., Ait‐Si‐Ali, S., Guglielmi, J., Arnold, C., Harel‐Bellan, A., Clézardin, P., & Cabon, F. (2003) · PubMed · Cited by 253
Taratula, O., Garbuzenko, O. B., Chen, A. M., & Minko, T. (2011) · Journal of Drug Targeting · doi:10.3109/1061186x.2011.622404 · Cited by 245
Self-Assembly of Polyamine−Poly(ethylene glycol) Copolymers with Phosphorothioate Oligonucleotides
Vinogradov, S. V., Bronich, T. K., & Kabanov, A. V. (1998) · Bioconjugate Chemistry · doi:10.1021/bc980048q · Cited by 244
Advances in chitosan-based drug delivery vehicles
Hu, L., Sun, Y., & Wu, Y. (2013) · Nanoscale · doi:10.1039/c3nr00338h · Cited by 243
Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer
MODOK, S., MELLOR, H., & CALLAGHAN, R. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.01.009 · Cited by 242
Antitumor Activity of Small Interfering RNA/Cationic Liposome Complex in Mouse Models of Cancer
Yano, J., Hirabayashi, K., Nakagawa, S.-I., Yamaguchi, T., Nogawa, M., Kashimori, I., Naito, H., Kitagawa, H., Ishiyama, K., Ohgi, T., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1049 · Cited by 238
The microRNA pathway and cancer
Kwak, P. B., Iwasaki, S., & Tomari, Y. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01683.x · Cited by 237
Cao, N., Cheng, D., Zou, S., Ai, H., Gao, J., & Shuai, X. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2010.11.061 · Cited by 229
Therapeutic Delivery of MicroRNA-29b by Cationic Lipoplexes for Lung Cancer
Wu, Y., Crawford, M., Mao, Y., Lee, R. J., Davis, I. C., Elton, T. S., Lee, L. J., & Nana-Sinkam, S. P. (2013) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2013.14 · Cited by 223
Chen, Y., Bathula, S. R., Li, J., & Huang, L. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.125906 · Cited by 216
Recent Advances in Protein and Peptide Drug Delivery: A Special Emphasis on Polymeric Nanoparticles
Patel, A., Patel, M., Yang, X., & Mitra, A. (2014) · Protein & Peptide Letters · doi:10.2174/0929866521666140807114240 · Cited by 209
MicroRNAs as potential cancer therapeutics
Trang, P., Weidhaas, J. B., & Slack, F. J. (2008) · Oncogene · doi:10.1038/onc.2009.353 · Cited by 208
Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges
Zhou, J., Shum, K.-T., Burnett, J., & Rossi, J. (2013) · Pharmaceuticals · doi:10.3390/ph6010085 · Cited by 205
Zheng, C., Zheng, M., Gong, P., Deng, J., Yi, H., Zhang, P., Zhang, Y., Liu, P., Ma, Y., & Cai, L. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.01.053 · Cited by 200
Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-delivery
Biswas, S., Deshpande, P. P., Navarro, G., Dodwadkar, N. S., & Torchilin, V. P. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2012.10.024 · Cited by 197
Preparation of poly ɛ-caprolactone nanoparticles containing magnetite for magnetic drug carrier
YANG, J., PARK, S., YOON, H., HUH, Y., & HAAM, S. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.06.029 · Cited by 194
In Vitro Targeting of Synthesized Antibody-Conjugated Dendrimer Nanoparticles
Thomas, T. P., Patri, A. K., Myc, A., Myaing, M. T., Ye, J. Y., Norris, T. B., & Baker, J. R. (2004) · Biomacromolecules · doi:10.1021/bm049704h · Cited by 193
Nanoparticles Targeted With NGR Motif Deliver c-myc siRNA and Doxorubicin for Anticancer Therapy
Chen, Y., Wu, J. J., & Huang, L. (2010) · Molecular Therapy · doi:10.1038/mt.2009.291 · Cited by 190
Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology
Xue, X., & Liang, X.-J. (2012) · Chinese Journal of Cancer · doi:10.5732/cjc.011.10326 · Cited by 187
Kaneshiro, T. L., & Lu, Z.-R. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.06.026 · Cited by 186
You, Y.-Z., Manickam, D. S., Zhou, Q.-H., & Oupický, D. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.04.020 · Cited by 185
Polymersome delivery of siRNA and antisense oligonucleotides
Kim, Y., Tewari, M., Pajerowski, J. D., Cai, S., Sen, S., Williams, J., Sirsi, S., Lutz, G., & Discher, D. E. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.10.020 · Cited by 184
Cheng, D., Cao, N., Chen, J., Yu, X., & Shuai, X. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2011.10.057 · Cited by 184
Applications of inorganic nanoparticles as therapeutic agents
Kim, T., & Hyeon, T. (2014) · Nanotechnology · doi:10.1088/0957-4484/25/1/012001 · Cited by 180
RNAi-based nanomedicines for targeted personalized therapy
Daka, A., & Peer, D. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.08.014 · Cited by 167
Osaka, T., Nakanishi, T., Shanmugam, S., Takahama, S., & Zhang, H. (2009) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2009.03.004 · Cited by 166
Pan, H., Liu, L., & Cai, L. (2022) · Biomaterial Engineering · doi:10.1007/978-981-16-5419-0_18 · Cited by 165
Liposomes: Versatile and Biocompatible Nanovesicles for Efficient Biomolecules Delivery
Mallick, S., & Choi, J. S. (2014) · Journal of Nanoscience and Nanotechnology · doi:10.1166/jnn.2014.9080 · Cited by 163
Kukowska‐Latallo, J. F. (2008) · International Journal of Nanomedicine · doi:10.2147/ijn.s2696 · Cited by 162
Effect of Polyethylene Glycol on Gene Delivery of Polyethylenimine.
Sung, S.-J., Min, S. H., Cho, K. Y., Lee, S., Min, Y.-J., Yeom, Y. I., & Park, J.-K. (2003) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.26.492 · Cited by 161
Chen, Y., Chen, H., & Shi, J. (2014) · Molecular Pharmaceutics · doi:10.1021/mp400596v · Cited by 158
Nanoparticles as Drug Delivery Systems in Cancer Medicine: Emphasis on RNAi-Containing Nanoliposomes
Díaz, M., & Vivas‐Mejía, P. E. (2013) · Pharmaceuticals · doi:10.3390/ph6111361 · Cited by 154
Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA
Yu, Y. H., Kim, E. J., Park, D. E., Shim, G., Lee, S. B., Kim, Y. B., Kim, C., & Oh, Y. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.11.002 · Cited by 154
Biodegradability of sol–gel silica microparticles for drug delivery
Finnie, K. S., Waller, D. J., Perret, F. L., Krause‐Heuer, A. M., Lin, H. Q., Hanna, J. V., & Barbé, C. J. (2008) · Journal of Sol-Gel Science and Technology · doi:10.1007/s10971-008-1847-4 · Cited by 151
de Martimprey, H., Vauthier, C., Malvy, C., & Couvreur, P. (2008) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.09.024 · Cited by 148
MicroRNA gets down to business
Mack, G. S. (2007) · Nature Biotechnology · doi:10.1038/nbt0607-631 · Cited by 148
RNA interference in biology and disease
Sledz, C. A., & Williams, B. R. G. (2005) · Blood · doi:10.1182/blood-2004-12-4643 · Cited by 147
Berns, A. J. M. (2005) · Nature · doi:10.1038/436787a · Cited by 146
Colley, H. E., Hearnden, V. L., Avila-Olias, M., Cecchin, D., Cantón, I., Madsen, J., MacNeil, S., Warren, N. J., Hu, K., McKeating, J. A., et al. (2014) · Molecular Pharmaceutics · doi:10.1021/mp400610b · Cited by 144
Wei, W., Lv, P., Chen, X.-M., Yue, Z., Fu, Q., Liu, S., Yue, H., & Ma, G. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.02.030 · Cited by 143
Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications
Huang, C., Li, M., Chen, C., & Yao, Q. C. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.5.637 · Cited by 140
Angiogenic Activity as a Marker of Neoplastic and Preneoplastic Lesions of the Human Bladder
Chodak, G. W., Haudenschild, C. C., Gittes, R. F., & Folkman, J. (1980) · Annals of Surgery · doi:10.1097/00000658-198012000-00012 · Cited by 139
Kim, H. R., Kim, I. K., Bae, K. H., Hyeon, L. S., Lee, Y., & Park, T. G. (2008) · Molecular Pharmaceutics · doi:10.1021/mp8000233 · Cited by 139
Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell properties
Taube, J. H., Malouf, G. G., Lu, E., Sphyris, N., Vijay, G. V., Ramachandran, P. P., Ueno, K. R., Gaur, S., Nicoloso, M. S., Rossi, S., et al. (2013) · Scientific Reports · doi:10.1038/srep02687 · Cited by 136
Cancer multidrug resistance: a review of recent drug discovery research.
Liscovitch, M., & Lavie, Y. (2002) · PubMed · Cited by 134
Fattal, E., & Bochot, A. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.06.011 · Cited by 124
Angiogenesis Induced by "Normal" Human Breast Tissue: A Probable Marker for Precancer
Jensen, H. M., Chen, I., DeVault, M. R., & Lewis, A. E. (1982) · Science · doi:10.1126/science.6181563 · Cited by 122
The significance of atypical vessels and neovascularization in cervical neoplasia
Sillman, F. H., Boyce, J. G., & Fruchter, R. G. (1981) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(81)90438-5 · Cited by 120
Tekade, R. K., Dutta, T., Tyagi, A., Bharti, A. C., Das, B. C., & Jain, N. K. (2008) · Journal of drug targeting · doi:10.1080/10611860802473154 · Cited by 115
Self-citationPerformance evaluation of PAMAM dendrimer based simvastatin formulations
Kulhari, H., Pooja, D., Prajapati, S. K., & Chauhan, A. S. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.12.002 · Cited by 113
Nanoparticles from renewable polymers
Wurm, F. R., & Weiss, C. K. (2014) · Frontiers in Chemistry · doi:10.3389/fchem.2014.00049 · Cited by 112
RNAi: a potential new class of therapeutic for human genetic disease
Seyhan, A. A. (2011) · Human Genetics · doi:10.1007/s00439-011-0995-8 · Cited by 112
Gou, M., Zheng, L., Peng, X.-Y., Men, K., Zheng, X., Zeng, S., Guo, G. F., Luo, F., Zhao, X., Chen, L., et al. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.04.007 · Cited by 111
Biocompatibility of chitosan-coated iron oxide nanoparticles with osteoblast cells
Zhang, X., Shi, S., Jia, Zhao, 。., Guo, Chen, Guo, & Cheng, C. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s34348 · Cited by 110
Yang, S., & May, S. (2008) · The Journal of Chemical Physics · doi:10.1063/1.3009263 · Cited by 108
Charge affects the oral toxicity of poly(amidoamine) dendrimers
Thiagarajan, G., Greish, K. F., & Ghandehari, H. (2013) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2013.01.019 · Cited by 104
Shim, G., Han, S.-E., Yu, Y.-H., Lee, S. B., Lee, H. Y., Kim, K., Kwon, I. C., Park, T. G., Kim, Y. B., Choi, Y. S., et al. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.10.017 · Cited by 103
Yin, Q., Shen, J., Chen, L., Zhang, Z., Gu, W., & Li, Y. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.05.039 · Cited by 100
Lv, P., Wei, W., Yue, H., Yang, T., Wang, L.-Y., & Ma, G. (2011) · Biomacromolecules · doi:10.1021/bm2010774 · Cited by 97
Nanoparticle Delivery of Pooled siRNA for Effective Treatment of Non-Small Cell Lung Caner
Yang, Y., Hu, Y., Wang, Y., Li, J., Liu, F., & Huang, L. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300152v · Cited by 97
Novel Cationic Lipid That Delivers siRNA and Enhances Therapeutic Effect in Lung Cancer Cells
Chen, Y., Sen, J., Bathula, S. R., Yang, Q., Fittipaldi, R., & Huang, L. (2009) · Molecular Pharmaceutics · doi:10.1021/mp800136v · Cited by 96
Sinek, J. P., Frieboes, H. B., Zheng, X., & Vittorio Cristini, C. (2004) · Biomedical Microdevices · doi:10.1023/b:bmmd.0000048562.29657.64 · Cited by 95
Polymer nanoparticle-mediated delivery of microRNA inhibition and alternative splicing
Cheng, C. J., & Saltzman, W. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300081s · Cited by 92
Inorganic Nanoparticle Biomolecular Corona: Formation, Evolution and Biological Impact
Casals, E., & Puntes, V. (2012) · Nanomedicine · doi:10.2217/nnm.12.169 · Cited by 92
Pangburn, T. O., Georgiou, K., Bates, F. S., & Kokkoli, E. (2012) · Langmuir · doi:10.1021/la300874z · Cited by 91
Deng, J., Gao, N., Wang, Y., Yi, H., Fang, S., Ma, Y., & Cai, L. (2012) · Biomacromolecules · doi:10.1021/bm3012538 · Cited by 91
Formulation Approaches to Short Interfering RNA and MicroRNA: Challenges and Implications
Guzman‐Villanueva, D., El-sherbiny, I. M., Herrera‐Ruiz, D., Vlassov, A. V., & Smyth, H. D. C. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23300 · Cited by 90
MicroRNA-like off-target transcript regulation by siRNAs is species specific
Burchard, J., Jackson, A. L., Malkov, V. A., Needham, R. H. V., Tan, Y., Bartz, S. R., Dai, H. A., Sachs, A. B., & Linsley, P. S. (2009) · RNA · doi:10.1261/rna.1326809 · Cited by 90
Cancer Chronotherapeutics: Experimental, Theoretical, and Clinical Aspects
Ortiz‐Tudela, E., Mteyrek, A., Ballesta, A., Innominato, P. F., & Lévi, F. (2013) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25950-0_11 · Cited by 84
siRNA, miRNA and HIV: promises and challenges
Yeung, M. L., Bennasser, Y., Le, S.-Y., & Jeang, K. (2005) · Cell Research · doi:10.1038/sj.cr.7290371 · Cited by 82
Innovative Strategy for MicroRNA Delivery in Human Mesenchymal Stem Cells via Magnetic Nanoparticles
Schade, A., Delyagina, E., Scharfenberg, D., Skorska, A., Lux, C. A., David, R., & Steinhoff, G. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140610710 · Cited by 78
Pharmaceutical and Biomedical Potential of Surface Engineered Dendrimers
Satija, J., Gupta, U. D., & Jain, N. K. (2007) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v24.i3.20 · Cited by 75
Shuai, X. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s29328 · Cited by 70
Development of recombinant cationic polymers for gene therapy research
Canine, B., & Hatefi, A. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.001 · Cited by 67
Synergistic and tumour selective effects of chemotherapy and ultrasound treatment
Myhr, G. E., & Moan, J. E. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.02.020 · Cited by 66
Dl, L., van der Meijden, A. P. M., Akaza, H., Brendler, C., Hedlund, P. O., Mizutani, Y., Ratliff, T. L., Robinson, M., & Shinka, T. (1995) · International Journal of Urology · doi:10.1111/j.1442-2042.1995.tb00069.x · Cited by 65
A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA.
Nakamura, K., Lila, A. A., Matsunaga, M., Doi, Y., Ishida, T., & Kiwada, H. (2011) · Molecular Therapy · doi:10.1038/mt.2011.174 · Cited by 64
Huang, H., Kuo, W., Chou, M., & Huang, Y. (2011) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.33055 · Cited by 61
Kang, S. H., Cho, H. J., Shim, G., Lee, S. B., Kim, S.-H., Choi, H.-G., Kim, C., & Oh, Y. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0569-4 · Cited by 60
Kim, H., Kim, E., An, Y., Choi, J., Jang, E., Choi, E. B., Kukreja, A., Kim, M.-H., Kang, B., Kim, D., et al. (2013) · Macromolecular Bioscience · doi:10.1002/mabi.201200448 · Cited by 59
Progress and Prospects of Polyplex Nanomicelles for Plasmid DNA Delivery
Itaka, K., & Kataoka, K. (2011) · Current Gene Therapy · doi:10.2174/156652311798192879 · Cited by 58
Solubility enhancement of paclitaxel using a linear-dendritic block copolymer
Zhou, Z., D’Emanuele, A., & Attwood, D. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.04.075 · Cited by 58
Orson, F. M., Kinsey, B. M., Hua, P., Bhogal, B. S., Densmore, C. L., & Barry, M. A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6313 · Cited by 56
RNAi nanomedicines: challenges and opportunities within the immune system
Weinstein, S., & Peer, D. (2010) · Nanotechnology · doi:10.1088/0957-4484/21/23/232001 · Cited by 52
Cited by
Nanostructured lipid carriers: Promising drug delivery systems for future clinics
Beloqui, A., Solinís, M. Á., Rodríguez-Gascón, A., Almeida, A. J., & Préat, V. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.09.004 · Cited by 769
Li, W., Zhang, H., Assaraf, Y. G., Zhao, K., Xu, X., Xie, J., Yang, D.-H., & Chen, Z.-S. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.05.001 · Cited by 673
Liang, G., Zhu, Y., Ali, D. J., Tian, T., Xu, H., Si, K., Sun, B., Chen, B., & Xiao, Z. (2020) · Journal of Nanobiotechnology · doi:10.1186/s12951-019-0563-2 · Cited by 619
Composition design and medical application of liposomes
Li, M., Du, C., Guo, N., Teng, Y., Meng, X., Sun, H., Li, S., Yu, P., & Galons, H. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.007 · Cited by 555
siRNA Delivery Strategies: A Comprehensive Review of Recent Developments
Tatiparti, K., Sau, S., Kashaw, S., & Iyer, A. (2017) · Nanomaterials · doi:10.3390/nano7040077 · Cited by 429
Metadata
- Authors
- Gandhi, N. S., Tekade, R. K., & Chougule, M. B.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2014-11
- Volume
- 194
- Pages
- 238-256
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2010731545
- Cited by
- 394
- References
- 218
- FWCI
- 17.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.